“…Several genomic alterations have been identified in OL, including single nucleotide variations and mutation hotspots in genes related to the cell cycle and cancer regulatory pathways, such as TP53, Ki-67, and NOTCH1 (Zhang et al, 2017;Ding et al, 2018;Yagyuu et al, 2017;Gissi et al, 2015). Loss of heterozygosity and changes in DNA methylation are also significantly associated with clinical outcomes in OL patients (Tsao et al, 2009;Zhou et al, 2011;Zhang et al, 2012;Türke et al, 2017). However, the frequencies of these mutations and altered biomarkers are low, and only a small number of OL cases harbor these genetic alterations (Mello et al, 2020).…”